Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002760 · ClinicalTrials.gov registry record · Phase 3
Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer
A Phase 3 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 3
- Development phase
- 260
- Enrollment target
NCT00002760: Completed Phase 3 study, sponsored by Alliance for Clinical Trials in Oncology.
NCT00002760 is a Phase 3 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 260 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (66% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002760, a Phase 3 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 260 participants
- Enrollment target
Study Summary
RATIONALE: Antiandrogen withdrawal may be an effective treatment for prostate cancer. PURPOSE: Randomized phase III trial to study the effectiveness of ketoconazole and hydrocortisone for antiandrogen withdrawal in treating men with prostate cancer that is refractory to hormone therapy.
Interventions
- DRUG ketoconazole
- DRUG therapeutic hydrocortisone
- OTHER Withdrawal of antiandrogen therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 1996-08 |
| Est. Completion | 2009-04 |
| Phase | Phase 3 |
What the finished NCT00002760 record still lists
NCT00002760 is an interventional study that assigns participants to a tested intervention. The registered 260 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (66% lower).
The record links to 0 conditions, and to 3 interventions - of which ketoconazole is the first listed.
NCT00002760 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002760 about?
NCT00002760 is a clinical study titled "Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer". RATIONALE: Antiandrogen withdrawal may be an effective treatment for prostate cancer. PURPOSE: Randomized phase III trial to study the effectiveness of ketoconazole and hydrocortisone for antiandrogen withdrawal in treating men with prostate cancer that is refractory to hormone therapy.
What is the current status of trial NCT00002760?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 260 participants. The study started on 1996-08. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00002760?
The interventions under investigation include: ketoconazole (DRUG), therapeutic hydrocortisone (DRUG), Withdrawal of antiandrogen therapy (OTHER).
Who is sponsoring clinical trial NCT00002760?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002760's enrollment target sits among peer trials
260 1230th of 2000 higher than 767 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02283996 · 260 participants · Phase 4
Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment
- NCT03276793 · 260 participants · NA
Brain Connectivity in Depression
- NCT03407469 · 260 participants
Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization
- NCT03713125 · 260 participants · NA
Executive Function in Early Childhood
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia